Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The new coronavirus crisis has upended the clinical trials process around the world.
Researchers used a harmless virus to deliver a gene for a broadly neutralizing HIV antibody to cells, which produced the antibody over time.
Temporarily off antiretrovirals, participants received antibody injections, which boosted CD4 and CD8 cell responses to HIV.
For the first time, researchers are assessing a pairing of a long-acting antiretroviral and a long-acting antibody.
An $80,000 grant from The Campbell Foundation will help scientist Natalia Freund continue her HIV vaccine studies.
A series of antibody infusions suppressed HIV for up to four months without prompting the virus to develop resistance.
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against HIV.
Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against the virus.
An antibody treatment plus an immune-stimulating agent delayed viral rebound in primates infected with HIV-like virus.
Periodic infusions of such antibodies may eventually become a new way of treating the virus.
Antibodies protect monkeys against SHIV.
This sets the stage for an early human trial of such antibody injections for use as pre-exposure prophylaxis (PrEP) against HIV.
Researchers are trying to harness the power of certain antibodies as long-acting injectable forms of HIV treatment or PrEP.
Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.